Brokerages Set Kyntra Bio Inc (NASDAQ:KYNB) PT at $30.00

Kyntra Bio Inc (NASDAQ:KYNB) has earned a consensus recommendation of “Moderate Buy” from the five research firms that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation, two have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $32.50.

Several equities research analysts have recently commented on KYNB shares. Rodman & Renshaw began coverage on shares of Kyntra Bio in a research note on Tuesday, June 9th. They set a “buy” rating and a $30.00 price objective for the company. Wall Street Zen raised Kyntra Bio from a “sell” rating to a “hold” rating in a research report on Saturday, April 18th. Oppenheimer assumed coverage on Kyntra Bio in a research report on Monday, July 6th. They issued an “outperform” rating and a $35.00 target price on the stock. Finally, Weiss Ratings restated a “sell (d)” rating on shares of Kyntra Bio in a research note on Tuesday, June 16th.

Kyntra Bio Stock Performance

NASDAQ:KYNB opened at $7.61 on Monday. Kyntra Bio has a twelve month low of $6.32 and a twelve month high of $12.60. The stock has a market cap of $30.81 million, a P/E ratio of 0.19 and a beta of 0.96. The stock’s 50 day moving average is $7.03.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Kyntra Bio stock. ADAR1 Capital Management LLC acquired a new position in Kyntra Bio Inc (NASDAQ:KYNB) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 10,469 shares of the company’s stock, valued at approximately $71,000. ADAR1 Capital Management LLC owned about 0.26% of Kyntra Bio as of its most recent SEC filing. 72.71% of the stock is currently owned by institutional investors and hedge funds.

About Kyntra Bio

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.